2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions

Ingelheim, Germany, 14 April 2020 – For the fifth year, Boehringer Ingelheim sponsors the European PRRS Research Award to support applied research for improved control of the PRRS swine disease (Porcine Reproductive and Respiratory Syndrome). Research proposals for the 2020 European PRRS Research Award can be submitted until 1 July 2020. Boehringer Ingelheim will provide three grants of 25,000 euros each to fund research proposals that will generate new and relevant data to better understand this devastating and costly disease.

The European PRRS Research Award aims at encouraging research for the discovery of practical application strategies to control PRRS and enhances the interaction among swine researchers and veterinarians. In addition, Boehringer Ingelheim’s intention is to further stimulate communication in the industry on practical PRRS control strategies and to reward research excellence. The PRRS viral disease infects pigs around the globe by causing respiratory tract illness in growing pigs and reproductive failure in breeding stock; Boehringer Ingelheim strives to find solutions for sustainable PRRS control.

Applications to submit research proposals should be sent via email to paulina.hoerstermann@boehringer-ingelheim.com. Further information on the submission process could be found on www.prrs.com. An independent review board will assess each proposal carefully. Members of the review board are highly recognized swine industry professionals including researchers and practitioners. The board will select proposals based on several factors, including their significance, potential for impact to the swine industry, originality and innovation.

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 markets.

As the lives of animals and humans are intertwined, across the globe, our 10,000 employees are dedicated to enhancing the well-being of both – through science and innovation, as well as with their commitment and passion.

Respect for animals, people and the environment is at the heart of what we do. We develop medicines, services and innovative digital technologies to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com.